We investigated the effect of mannan-binding lectin (MBL) deficiency on the susceptibility to bypass graft occlusion in 62 patients with coronary heart disease. MBL deficiency appeared to be associated with occlusion (p = 0.0099). A high level of anti-cardiolipin IgG as well as the number of venous bypass grafts were also involved (p = 0.0018 and p = 0.0104, respectively). Since early occlusion (<5 years after surgery) of a venous bypass graft is considered to be caused by thrombosis or fibro-intimal hyperplasia superimposed by thrombosis, our finding also implies an association of MBL deficiency with thrombotic events. It remains unclear whether the previously confirmed effect of MBL deficiency in coronary disease is mediated through this possible thrombotic mechanism, or whether plaque formation is also involved in the process. Further studies are clearly warranted.

Keywords:
Anti-β2-glycoprotein I antibodies, Anti-cardiolipin antibodies, Coronary heart disease, Mannan-binding lectin, Thrombosis, Venous bypass graft occlusion
1.
Cox JL, Chiasson DA, Gotlieb AI: Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991;34:45–68.
2.
Morton KE, Gavaghan TP, Krilis SA, Daggard GE, Baron DW, Hickie JB, Chesterman CN: Coronary artery bypass graft failure – An autoimmune phenomenon? Lancet 1986;ii:1353–1357.
3.
Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T: Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23–27.
4.
Turner MW, Hamvas RMJ: Mannose-binding lectin: Structure, function, genetics and disease associations. Rev Immunogenet 2000;2:305–322.
5.
Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P: Association of mannose-binding lectin deficiency with severe atherosclerosis. Lancet 1998;352:959–960.
6.
Hegele RA, Ban MR, Anderson CM, Spence JD: Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Investig Med 2000;48:198–202.
7.
Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;ii:983–986.
8.
Swanson AF, Ezekowitz RA, Lee A, Kuo CC: Human mannose-binding protein inhibits infection of HeLa cells by Chlamydia trachomatis. Infect Immun 1998;66:1607–1612.
9.
Kohler HP, Grant PJ: Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792–1801.
10.
Aittoniemi J, Miettinen A, Laippala P, Isolauri E, Viikari J, Ruuska T, Soppi E: Age-dependent variation in the serum concentration of mannan-binding protein. Acta Paediatr 1996;85:906–909.
11.
Harris NE, Pierangeli S, Birch D: Anticardiolipin wet workshop report: Fifth International Symposium on Antiphospholipid Antibodies. Immunopathology 1993;101:616–624.
12.
Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T: Antibodies to prothrombin imply a risk factor for myocardial infarction in middle-aged men. Thromb Haemost 1996;75:456–459.
13.
Kilpatrick DC, Bevan BH, Liston WA: Association between mannan binding protein deficiency and recurrent miscarriage. Hum Reprod 1995;10:2501–2505.
14.
Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC: Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand J Immunol 1999;49:193–196.
15.
Kilpatrick DC, Starrs L, Moore S, Souter V, Liston WA: Mannan binding lectin concentration and risk of miscarriage. Hum Reprod 1999;14:2379–2380.
16.
Haurum JS, Thiel S, Haagsman HP, Laursen SB, Larsen B, Jensenius JC: Studies on the carbohydrate-binding characteristics of human pulmonary surfactant-associated protein A and comparison with two other collectins: Mannan-binding protein and conglutinin. Biochem J 1993;293:873–878.
17.
Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1:237–243.
18.
Kilpatrick DC: Phospholipid-binding activity of human mannan-binding lectin. Immunol Lett 1998;61:191–195.
19.
Muller MM, Griesmacher A: Markers of endothelial dysfunction. Clin Chem Lab Med 2000;38:77–85.
20.
Anderson CL: Human IgG Fc receptors. Clin Immunol Immunopathol 1989;53:S63–S71.
21.
Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW: Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Immunology 1995;85:660–667.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.